According to the announcement of China Securities Network (reporter Kong Ziyuan) Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , on January 7, 2022, the holding subsidiary Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) industry and MPP signed a sublicense agreement on the authorized production of covid-19 oral drug molnupiravir. MPP grants the company’s holding subsidiary Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) industry a non exclusive license to use relevant patents and know-how to produce, commercialize and related rights of covid-19 oral drug molnupiravir (hereinafter referred to as “Cooperative Drug”) in the region. Molnupiravir is an oral ribonucleoside drug jointly developed by mosadon and Ridgeback. It can inhibit the replication of sars-cov-2 (the pathogenic factor of covid-19 virus). At present, it is mainly used to treat mild to moderate covid-19 pneumonia.
This license is non exclusive; The licensed areas are 105 low-income countries / regions such as India, Pakistan and C ô te d’Ivoire, excluding China. Before the commercial production of cooperative drugs under this license, relevant technical handover needs to be completed, and the production facilities need to be approved by SRA or certified by who PQ. The production and sales of cooperative drugs in the region under this license can only be implemented after the approval of relevant competent authorities (including but not limited to marketing approval). As of the date of this announcement, the company has no orders in hand for cooperative drugs and has not carried out relevant production. The impact of this license on the company’s current and future revenue and profits cannot be predicted.
